|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 471.66 USD | -0.85% |
|
-3.75% | -3.05% |
Evolution of the Average Target: United Therapeutics Corporation
Evolution of the Target Price: United Therapeutics Corporation
Changes in Analyst Recommendations: United Therapeutics Corporation
| Consensus | Analysts' recommendations evolution (4 months) | Financial estimates divergence | Analysts' Target price divergence | Objective/dr gap | ||
|---|---|---|---|---|---|---|
 | +11.64% | |||||
| +4.01% | |||||
| -3% | |||||
| +10.23% | |||||
| -2.56% | |||||
| +5.65% | |||||
| -5.45% | |||||
| +2.09% | |||||
| +3.38% | |||||
| +0.8% | |||||
| Average | +2.68% | |||||
| Weighted average by Cap. | +2.07% |
Analysts' Consensus
Analyst Consensus Detail
Consensus revision (last 18 months)
Analysts covering the company
| UBS | |
| BofA Securities | |
| RBC Capital Markets | |
| Oppenheimer | |
| TD Cowen | |
| Cantor Fitzgerald | |
| Wells Fargo Securities | |
| Goldman Sachs | |
| Leerink Partners | |
| Wedbush | |
| Morgan Stanley | |
| Ladenburg Thalmann | |
| Argus | |
| Credit Suisse | |
| HC Wainwright | |
| Jefferies & Co. | |
| JPMorgan Chase | |
| BTIG | |
| J.P. Morgan Chase |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- UTHR Stock
- Consensus United Therapeutics Corporation
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition